Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
May 09, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase 2 study in patients with biliary tract...
May 05, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics to Present at the Bank of America Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 11:20 a.m. PT

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
May 04, 2022 07:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies ...
May 03, 2022 16:01 ET | Source: Compass Therapeutics

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...
April 26, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Appointment of Two New Directors to its Board

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
April 08, 2022 13:01 ET | Source: Compass Therapeutics

Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to...
March 30, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based therapeutics to...
March 21, 2022 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
January 20, 2022 08:30 ET | Source: Compass Therapeutics

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...

keyboard_arrow_left Previous Page